X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs WOCKHARDT LTD. - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA WOCKHARDT LTD. CIPLA/
WOCKHARDT LTD.
 
P/E (TTM) x 44.7 -15.5 - View Chart
P/BV x 3.8 2.5 151.1% View Chart
Dividend Yield % 0.3 1.3 25.8%  

Financials

 CIPLA   WOCKHARDT LTD.
EQUITY SHARE DATA
    CIPLA
Mar-17
WOCKHARDT LTD.
Mar-17
CIPLA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs6221,129 55.1%   
Low Rs458627 73.1%   
Sales per share (Unadj.) Rs181.9363.1 50.1%  
Earnings per share (Unadj.) Rs12.9-20.4 -62.9%  
Cash flow per share (Unadj.) Rs29.3-7.0 -420.3%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.41.1 32.5%  
Book value per share (Unadj.) Rs155.7301.8 51.6%  
Shares outstanding (eoy) m804.51110.55 727.7%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x3.02.4 122.8%   
Avg P/E ratio x42.0-42.9 -97.7%  
P/CF ratio (eoy) x18.4-125.9 -14.6%  
Price / Book Value ratio x3.52.9 119.3%  
Dividend payout %15.5-48.9 -31.8%   
Avg Mkt Cap Rs m434,51697,063 447.7%   
No. of employees `00023.06.8 340.5%   
Total wages/salary Rs m26,3389,665 272.5%   
Avg. sales/employee Rs Th6,349.15,931.8 107.0%   
Avg. wages/employee Rs Th1,143.01,428.1 80.0%   
Avg. net profit/employee Rs Th449.3-334.0 -134.5%   
INCOME DATA
Net Sales Rs m146,30240,146 364.4%  
Other income Rs m2,2871,143 200.2%   
Total revenues Rs m148,58941,289 359.9%   
Gross profit Rs m24,758128 19,342.1%  
Depreciation Rs m13,2291,489 888.3%   
Interest Rs m1,5942,253 70.8%   
Profit before tax Rs m12,222-2,472 -494.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,798-211 -851.5%   
Profit after tax Rs m10,354-2,260 -458.1%  
Gross profit margin %16.90.3 5,307.6%  
Effective tax rate %14.78.5 172.2%   
Net profit margin %7.1-5.6 -125.7%  
BALANCE SHEET DATA
Current assets Rs m87,37046,160 189.3%   
Current liabilities Rs m33,08119,258 171.8%   
Net working cap to sales %37.167.0 55.4%  
Current ratio x2.62.4 110.2%  
Inventory Days Days87101 86.3%  
Debtors Days Days6294 66.2%  
Net fixed assets Rs m111,56740,165 277.8%   
Share capital Rs m1,609553 291.1%   
"Free" reserves Rs m123,64532,814 376.8%   
Net worth Rs m125,25433,367 375.4%   
Long term debt Rs m36,45431,903 114.3%   
Total assets Rs m209,53289,687 233.6%  
Interest coverage x8.7-0.1 -8,924.6%   
Debt to equity ratio x0.31.0 30.4%  
Sales to assets ratio x0.70.4 156.0%   
Return on assets %5.70 -66,417.6%  
Return on equity %8.3-6.8 -122.0%  
Return on capital %8.5-0.3 -2,535.7%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,0669,121 559.9%   
Fx outflow Rs m17,6782,133 828.7%   
Net fx Rs m33,3886,988 477.8%   
CASH FLOW
From Operations Rs m23,824-2,695 -884.1%  
From Investments Rs m-13,127-6,863 191.3%  
From Financial Activity Rs m-13,23912,545 -105.5%  
Net Cashflow Rs m-2,4783,010 -82.3%  

Share Holding

Indian Promoters % 16.0 74.5 21.5%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 2.3 530.4%  
FIIs % 23.7 7.7 307.8%  
ADR/GDR % 1.1 0.1 1,100.0%  
Free float % 26.2 15.4 170.1%  
Shareholders   161,166 67,757 237.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  AJANTA PHARMA  UNICHEM LAB  

Compare CIPLA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Down Around 1%; Telecom & Metal Stocks Decline(01:30 pm)

Indian share markets are trading in the red presently. Sectoral indices are trading in the red with stocks in the telecom sector and metal sector witnessing maximum selling pressure.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 19, 2018 02:13 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS